Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegylated Interferon · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pegylated Interferon | DRUG | - |
| Lamivudine | DRUG | - |
Inclusion Criteria: * HBsAg positive for at least 6 months prior to screening * Serum HBV-DNA \> 10\^6 copies per ml at screening * Serum HBeAg positive at screening * Abnormal ALT (1.3-10x upper limit normal) within one month prior to entry * Compensated liver disease with the following minimum cr...
Pegylated Interferon is used for the treatment of Chronic Hepatitis B, a viral infection that affects the liver. It is being investigated as a therapy to manage this condition, with clinical trials evaluating its effectiveness in patients with the disease.
Pegylated Interferon is being developed by GSK plc, a global biopharmaceutical company. GSK is conducting clinical research to evaluate the drug's potential in treating Chronic Hepatitis B, with the company's stock traded under the ticker symbol GSK.
Pegylated Interferon is currently in Phase 2 clinical development for Chronic Hepatitis B. This means it is in the second stage of human testing, where researchers are evaluating its efficacy and safety in a larger group of patients. It is still investigational and not yet approved for commercial use.
Pegylated Interferon has been studied in a completed Phase 2 clinical trial with the identifier NCT00226447. This trial, titled "Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients," enrolled 30 participants in China and evaluated the drug's effects in adults aged 18 years and older.
Pegylated Interferon is a specific form of interferon that has been modified with polyethylene glycol to extend its activity in the body. While it belongs to the broader class of interferon therapies, it is distinct in its formulation and is being studied specifically for Chronic Hepatitis B.